Navigation Links
Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
Date:5/7/2012

MARLBOROUGH, Mass., May 7, 2012 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that its technology will be highlighted both as part of the scientific sessions and during a private academic symposium at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, May 9-12 in Boston, MA. The presentations will feature clinical experiences and outcomes using the company's technology, the first visually-guided laser balloon ablation system.

"We are pleased that over two years of comprehensive clinical experiences with our technology will be featured at this prominent industry conference. Many of the leading international experts in heart rhythm management will be participating in these sessions and presenting their own findings with the HeartLight EAS, and we anticipate engaging discussion on the applicability of the system in clinical practice," said Stephen Sagon, President and CEO of CardioFocus.

During the scientific sessions, the presentation "Worldwide Experience Using the Endoscopic Ablation System for Ablation of Atrial Fibrillation" will give an overview of the feasibility and safety of AF ablation using the HeartLight EAS, with findings representing the first patients treated with the technology by 32 different operators across 19 medical centers. The presentation will be made by Boris Schmidt, MD, of Cardioangiologisches Centrum Bethanien, Frankfurt, Germany on Friday, May 11 at 3:25 p.m. ET.

The HeartLight EAS Symposium, to be held the evening of Thursday, May 10 at the Renaissance Boston Waterfront Hotel, will feature presentations from cardiology thought leaders on the evolution of pulmonary vein (PV) isolation ablation, the adoption of the new visually-guided laser balloon ablation technique, and the clinical experiences with the technology at centers throughout Europe. It will be chaired by Prof. Petr Neuzil, MD, of Na Homolce Hospital, Prague, Czech Republic and Prof. Thorsten Lewalter, MD, of Isar Heart Center, Munich, Germany.

The HeartLight EAS is a unique catheter ablation technology that incorporates an endoscope for direct visualization of the inside of the heart and a compliant, dynamically adjustable balloon catheter designed for improved contact with the PV ostium irrespective of the individual patient anatomy. It also utilizes laser energy for more efficient, durable and precise ablation treatment. 

The system is available in Europe for the treatment of AF, and is currently the focus of a pivotal trial in the U.S. For more information, please visit the CardioFocus booth #1103 or www.CardioFocus.com.

About CardioFocus, Inc.CardioFocus, Inc. is a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). Its novel HeartLight® Endoscopic Ablation System for catheter ablation incorporates an endoscope to provide physicians with the capacity to see within the heart, and for the first time, visually direct the application of laser energy to achieve durable pulmonary vein isolation.

The HeartLight Endoscopic Ablation System is commercially available at leading institutions throughout Europe. The device is investigational in the U.S., and currently the focus of a pivotal trial initiated in 2012. CardioFocus is headquartered in Marlborough, MA, USA.  For more information on the company and its technology, please visit www.CardioFocus.com.

The scientific information discussed in this news release is preliminary and investigative. The CardioFocus HeartLight Endoscopic Ablation System is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the system. Only FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to/rely upon FDA-approved labeling for the products, and not the information discussed in this news release.Company Contact:

Media Contact:Anjie Roldan

Lisa CookVice President Finance

(646) 536-7012(508) 658-7237

lcook@theruthgroup.com aroldan@cardiofocus.com
'/>"/>

SOURCE CardioFocus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telemedicine Monitoring: Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018
2. ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report
3. Leading Pharma Events CPhI Worldwide, ICSE, P-MEC Europe & InnoPack to Return to Frankfurt in 2013 after Record Breaking Year
4. Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company
5. Cardica Achieves Key Milestone With Over 25,000 PAS-Port® Proximal Anastomosis Systems Deployed Worldwide
6. UH Case Medical Center the First in Region to Enroll Patients in Worldwide Study
7. Thermogenesis Signs Worldwide Res-Q System Distribution Agreement With Arthrex for Sports Medicine Applications
8. The Outlook for Medical Devices Worldwide
9. The Outlook for Pharmaceuticals Worldwide
10. BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine
11. Medical Centers Worldwide Adopt Both Accurays CyberKnife and TomoTherapy Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
Breaking Medicine Technology:
(Date:5/27/2016)... SC (PRWEB) , ... May 27, 2016 , ... ... a line of classic American timber frame barn kits, which can be found on ... are inspired by historic American barn plans, and they highlight the craftsmanship of timber ...
(Date:5/27/2016)... ... ... An influential resource amongst nurses and professionals in the health care world, ... of topics detailing why we appreciate nurses in so many different ways. From exclusive ... being in a major recession to one of the hottest growing professions in any ...
(Date:5/27/2016)... ... May 27, 2016 , ... An ... bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It ... leading advocates, associations and industry leaders such as Bioness. , As patients ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... installment is bolstered by inspiring human interest stories, courtesy of leaders in the ... and tech within the industry, from leading advocates and associations—namely Jones & Bartlett ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... the pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center ... proof of successfully certified products, services and staff. , Validation Center is ISO17025 ...
Breaking Medicine News(10 mins):